If that possibility is the case, pharmacotherapy for Charles Bonnet syndrome can be applied to some patients with probable Alzheimer’s disease when glasses and cataract surgery turn out to be useless, because some patients with Charles Bonnet syndrome do not respond to glasses and cataract surgery and need pharmacotherapy. At present there are several candidate treatments for Charles Bonnet syndrome, such as carbamazepine (3, 4), carbamazepine plus clonazepam (5), and valproate (unpublished data). These drugs are anticonvulsants, but they may be effective for the treatment of Charles Bonnet syndrome. These may be more effective and be associated with fewer side effects than neuroleptics for visual hallucinations in Alzheimer’s disease patients. Since these treatments are not established, it is necessary to perform randomized placebo- or neuroleptic-controlled, double-blind studies to investigate the side effects of these drugs and their effects on visual hallucinations in Alzheimer’s disease as well as in Charles Bonnet syndrome.